Table 1_Efficacy and safety of combined immune therapy for advanced cervical cancer: a sys

A systematic review and meta-analysis of 18 clinical trials involving 4,441 participants, assessing the efficacy and safety of immune checkpoint inhibitor (ICI) combination therapies for advanced cervical cancer. The study, authored by Fan Shi and uploaded to figshare, analyzes outcomes including objective response rate, progression-free survival, and adverse events. The data was last updated on May 25, 2026.

Use Cases

• Compare the efficacy of single versus dual ICI combination regimens based on reported hazard ratios for overall survival and progression-free survival.
• Analyze the relationship between patient subgroups (e.g., PD-L1+ status, age, histology) and treatment outcomes based on the subgroup analysis described.
• Assess the safety profile of ICI-based therapies based on reported rates of treatment-related and immune-related adverse events.
• Validate meta-analysis findings for advanced cervical cancer treatment using the aggregated data from 18 trials.

Strengths

• Aggregates data from 18 clinical trials, providing a substantial evidence base.
• Includes results for 4,441 participants, offering a meaningful sample size for analysis.
• Reports specific statistical measures such as hazard ratios and confidence intervals for key outcomes like overall survival and progression-free survival.
• Conducts predefined subgroup analyses based on PD-L1 expression, patient age, and tumor histology.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 4.8 MB DOCX file, which is a small dataset and may require parsing to extract structured data.

Provenance

Source

Systematic review of literature from PubMed, Web of Science, Embase, and Cochrane Library.

Collection Method

Meta-analysis conducted following PRISMA guidelines.

Freshness

Last updated 2026-05-25 06:10:56; freshness should be verified.